This site is intended for healthcare professionals
EMC Drug Feed
Drug information

Aqueous Calamine

OTC
Read time: 1 mins
Last updated: 06 Sep 2019
...
 

Summary of product characteristics


1. Name of the medicinal product

Aqueous Calamine Cream BP


2. Qualitative and quantitative composition

Calamine 4.0% w/w and Zinc Oxide 3.0% w/w

Excipient(s) with specified warnings

Cetostearyl alcohol 4.0% w/w

For the full list of excipients, see section 6.1.


3. Pharmaceutical form

Cream


4.1. Therapeutic indications

For relief of the symptoms of mild sunburn and other minor skin conditions.


4.2. Posology and method of administration

Topical application.

Adults, elderly and children: apply liberally to dry, clean skin as required.


4.3. Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.


4.4. Special warnings and precautions for use

For external use only.

Keep securely closed when not in use.

Keep out of the sight and reach of children.

Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

Ingredients with specified warnings

This medicine contains Cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).


4.5. Interaction with other medicinal products and other forms of interaction

May mask x-ray pictures under certain circumstances.


4.6. Fertility, pregnancy and lactation

No information is available on the use of this product during pregnancy and lactation. However, it is unlikely that its use would cause any adverse effects.


4.7. Effects on ability to drive and use machines

None known


4.8. Undesirable effects

Occasional hypersensitivity or irritant reactions

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.


4.9. Overdose

Not applicable


5.1. Pharmacodynamic properties

Both Zinc Oxide and Calamine exhibit a mild astringent action when applied to the skin.


5.2. Pharmacokinetic properties

None stated.


5.3. Preclinical safety data

None


6.1. List of excipients

Liquid paraffin, glyceryl monostearate, macrogol cetostearyl ether 22, cetostearyl alcohol, phenoxyethanol, purified water


6.2. Incompatibilities

None known


6.3. Shelf life

36 months unopened

Use within 12 months of first opening


6.4. Special precautions for storage

Do not store above 25°C.

Do not allow to freeze.


6.5. Nature and contents of container

100g: White polyethylene/Aluminium/co-polymer MDPE laminated plastic tube, with polypropylene cap.


6.6. Special precautions for disposal and other handling

None


7. Marketing authorisation holder

Thornton & Ross Ltd.

Linthwaite Laboratories

Huddersfield

HD7 5QH


8. Marketing authorisation number(s)

PL 00240/6276R


9. Date of first authorisation/renewal of the authorisation

15/06/1988 / 15/06/2001


10. Date of revision of the text

04/09/2019

4.1 Therapeutic indications

For relief of the symptoms of mild sunburn and other minor skin conditions.

4.2 Posology and method of administration

Topical application.

Adults, elderly and children: apply liberally to dry, clean skin as required.

4.3 Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

For external use only.

Keep securely closed when not in use.

Keep out of the sight and reach of children.

Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

Ingredients with specified warnings

This medicine contains Cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).

4.5 Interaction with other medicinal products and other forms of interaction

May mask x-ray pictures under certain circumstances.

4.6 Fertility, pregnancy and lactation

No information is available on the use of this product during pregnancy and lactation. However, it is unlikely that its use would cause any adverse effects.

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

Occasional hypersensitivity or irritant reactions

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.

Drug section

Clinical trials
Clinical trial
Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis

The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.

2 mins
Clinical trial
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.

2 min
Clinical trial
A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (HiTS)

The purpose of this study is to determine whether ustekinumab is effective in the treatment of moderate to severe hidradenitis...

1 min
Journals
Journal
Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions

Objective: We sought to evaluate the efficacy and patient satisfaction of the deroofing technique for recurrent Hurley I (mild) or II (moderate) graded HS lesions at fixed locations.

1 mins
Journal
Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management

<p>The recognition of the central role of interleukin 17A (IL-17A) in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes.</p>

1 min
Journal
Morbidity in patients with hidradenitis suppurativa

Objectives: To measure the impairment of life quality in patients with HS.

1 min
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).